Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
78% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s 10-Year Cash to Debt Range
Min: 0.11   Max: No Debt
Current: No Debt

Equity to Asset 0.78
CRMD's Equity to Asset is ranked higher than
64% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRMD: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s 10-Year Equity to Asset Range
Min: -1.36   Max: 0.82
Current: 0.78

-1.36
0.82
F-Score: 5
Z-Score: 35.61
M-Score: 18.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -5512.02
CRMD's Operating margin (%) is ranked lower than
89% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. CRMD: -5512.02 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s 10-Year Operating margin (%) Range
Min: -245750   Max: -4710.05
Current: -5512.02

-245750
-4710.05
Net-margin (%) -4441.35
CRMD's Net-margin (%) is ranked lower than
88% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CRMD: -4441.35 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s 10-Year Net-margin (%) Range
Min: -456650   Max: -10821.69
Current: -4441.35

-456650
-10821.69
ROE (%) -402.42
CRMD's ROE (%) is ranked lower than
96% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. CRMD: -402.42 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s 10-Year ROE (%) Range
Min: -899.21   Max: -158.05
Current: -402.42

-899.21
-158.05
ROA (%) -116.31
CRMD's ROA (%) is ranked lower than
88% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. CRMD: -116.31 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s 10-Year ROA (%) Range
Min: -507.14   Max: -117.7
Current: -116.31

-507.14
-117.7
ROC (Joel Greenblatt) (%) -25706.28
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CRMD: -25706.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -77336.36   Max: -23122.08
Current: -25706.28

-77336.36
-23122.08
EBITDA Growth (3Y)(%) 14.70
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CRMD: 14.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -66.3   Max: 14.7
Current: 14.7

-66.3
14.7
EPS Growth (3Y)(%) 18.30
CRMD's EPS Growth (3Y)(%) is ranked higher than
74% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CRMD: 18.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.4   Max: 18.3
Current: 18.3

-68.4
18.3
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRMD Guru Trades in Q2 2014

Paul Singer 781,440 sh (unchged)
» More
Q3 2014

CRMD Guru Trades in Q3 2014

Paul Singer 781,440 sh (unchged)
» More
Q4 2014

CRMD Guru Trades in Q4 2014

Paul Singer 781,440 sh (unchged)
» More
Q1 2015

CRMD Guru Trades in Q1 2015

Jim Simons 47,600 sh (New)
Paul Singer 1,500,200 sh (+91.98%)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 22.50
CRMD's P/B is ranked lower than
97% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CRMD: 22.50 )
Ranked among companies with meaningful P/B only.
CRMD' s 10-Year P/B Range
Min: 0   Max: 61.5
Current: 22.5

0
61.5
P/S 653.20
CRMD's P/S is ranked lower than
104% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. CRMD: 653.20 )
Ranked among companies with meaningful P/S only.
CRMD' s 10-Year P/S Range
Min: 0   Max: 10793.6
Current: 653.2

0
10793.6
Current Ratio 4.57
CRMD's Current Ratio is ranked higher than
52% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CRMD: 4.57 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s 10-Year Current Ratio Range
Min: 0.1   Max: 10.33
Current: 4.57

0.1
10.33
Quick Ratio 4.35
CRMD's Quick Ratio is ranked higher than
51% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. CRMD: 4.35 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s 10-Year Quick Ratio Range
Min: 0.1   Max: 10.33
Current: 4.35

0.1
10.33
Days Inventory 371.31
CRMD's Days Inventory is ranked lower than
89% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. CRMD: 371.31 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s 10-Year Days Inventory Range
Min: 72.28   Max: 222.19
Current: 371.31

72.28
222.19
Days Sales Outstanding 121.08
CRMD's Days Sales Outstanding is ranked lower than
78% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. CRMD: 121.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s 10-Year Days Sales Outstanding Range
Min: 154.5   Max: 365
Current: 121.08

154.5
365

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.10
CRMD's Price/Net Cash is ranked lower than
79% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: 14.50 vs. CRMD: 25.10 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s 10-Year Price/Net Cash Range
Min: 2.11   Max: 41
Current: 25.1

2.11
41
Price/Net Current Asset Value 24.10
CRMD's Price/Net Current Asset Value is ranked lower than
78% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: 10.20 vs. CRMD: 24.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s 10-Year Price/Net Current Asset Value Range
Min: 2.05   Max: 36.44
Current: 24.1

2.05
36.44
Price/Tangible Book 22.30
CRMD's Price/Tangible Book is ranked lower than
98% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. CRMD: 22.30 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 15.17
Current: 22.3

2.05
15.17
Earnings Yield (Greenblatt) -6.20
CRMD's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CRMD: -6.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CRMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -34.6   Max: 0
Current: -6.2

-34.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
CorMedix Receives Approval From FDA to Initiate a Clinical Trial for Neutrolin in the US Oct 27 2014 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
Why CorMedix (CRMD) Could Be Positioned for a Slump - Tale of the Tape May 22 2015
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 21 2015
CORMEDIX INC. Files SEC form 8-K, Other Events May 19 2015
CORMEDIX INC. Financials May 15 2015
CORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition May 08 2015
CORMEDIX INC. Files SEC form 10-Q, Quarterly Report May 07 2015
Q1 2015 CorMedix Inc Earnings Release - Time Not Supplied May 07 2015
Cormedix downgraded by ROTH Capital May 06 2015
CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015 May 05 2015
Oncolytics' Reolysin Gets Another Orphan Drug Status in EU - Analyst Blog May 01 2015
SurModics Misses on Q2 Earnings, Reaffirms 2015 Guidance - Analyst Blog May 01 2015
Celgene Beats on Q1 Earnings, Misses Revenues, Keeps View - Analyst Blog Apr 30 2015
Synageva Q1 Loss Narrower-than-Expected, Pipeline in Focus - Analyst Blog Apr 30 2015
Vertex Posts Wider 1Q Loss, Affirms Kalydeco Outlook - Analyst Blog Apr 30 2015
Aeterna Zentaris to Continue Phase III Study of Cancer Drug - Analyst Blog Apr 29 2015
BioMarin Upgraded to Strong Buy, Is It in Your Portfolio? - Analyst Blog Apr 29 2015
RedHill Finishes Patient Enrollment for RHB-105 Study - Analyst Blog Apr 28 2015
Aerie (AERI) Plunges on Disappointing Rhopressa Data - Analyst Blog Apr 27 2015
Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog Apr 23 2015
Ultragenyx Announces Positive Data from Triheptanoin Study - Analyst Blog Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK